naa a22 4500 510764126 CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130801xx s 000 0 eng 10.1007/s12094-012-0980-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0980-2 A study of circulating anti-CD25 antibodies in non-small cell lung cancer [Elektronische Daten] [L. Ye, X. Li, S. Sun, S. Guan, M. Wang, X. Guan, K.-H. Lee, J. Wei, B. Liu] Purpose: Tumors can trigger specific immune response to tumor-associated antigens but the precise mechanism remains unclear. Since regulatory T-lymphocytes (Treg) play a crucial role in controlling autoimmune responses, the present work was undertaken to test whether dysfunction of Treg cells could be involved in developing autoimmunity in patients with lung cancer. Methods: In this study, we developed an in-house enzyme-linked immunosorbent assay to test circulating anti-CD25 autoantibodies among 272 patients with non-small cell lung cancer (NSCLC) and 226 control subjects matched in age, gender and smoking history. Results: Mann-Whitney U test showed that the anti-CD25 IgG level was significantly higher in patients with NSCLC than control subjects (Z=−7.48, P<0.001) while the anti-CD25 IgA level was not significantly changed in the patient group as compared with the control group (Z=−1.34, P=0.181). Spearman correlation analysis failed to reveal a significant correlation between the levels of anti-CD25 IgG and IgA either in patients with NSCLC (r=−0.034, P=0.578) or in control subjects (r=0.055, P=0.429). ROC analysis showed an AUC of 0.70 for anti-CD25 IgG, in which NSCLC at stage III had the highest AUC (0.75). The sensitivity against a specificity of >90% was 35.0% for anti-CD25 IgG assay with an inter-assay deviation of 9.4%, and 4.0% for anti-CD25 IgA assay with an inter-assay deviation of 13.0%. Conclusions: Circulating anti-CD25 IgG antibody may be a useful biomarker for prognosis of lung cancer. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Autoantibody nationallicence Biomarker nationallicence CD25 nationallicence Lung cancer nationallicence Tumor immunity nationallicence Ye L. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut Li X. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut Sun S. Department of Radiobiology, School of Public Health, Jilin University, 130021, Changchun, People's Republic of China aut Guan S. Department of Radiobiology, School of Public Health, Jilin University, 130021, Changchun, People's Republic of China aut Wang M. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut Guan X. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut Lee K.-H Pei-Ling Guan-Si Hospital, Hsin-Fu Kuansi Township, 30647, Hsinchu County, Taiwan aut Wei J. Department of Diabetes and Cardiovascular Science, University of the Highlands and Islands, Centre for Health Science, IV2 3JH, Inverness, UK aut Liu B. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 633-637 1699-048X 15:8<633 2013 15 12094 https://doi.org/10.1007/s12094-012-0980-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0980-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ye L. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut NATIONALLICENCE 700 1- Li X. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut NATIONALLICENCE 700 1- Sun S. Department of Radiobiology, School of Public Health, Jilin University, 130021, Changchun, People's Republic of China aut NATIONALLICENCE 700 1- Guan S. Department of Radiobiology, School of Public Health, Jilin University, 130021, Changchun, People's Republic of China aut NATIONALLICENCE 700 1- Wang M. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut NATIONALLICENCE 700 1- Guan X. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut NATIONALLICENCE 700 1- Lee K.-H Pei-Ling Guan-Si Hospital, Hsin-Fu Kuansi Township, 30647, Hsinchu County, Taiwan aut NATIONALLICENCE 700 1- Wei J. Department of Diabetes and Cardiovascular Science, University of the Highlands and Islands, Centre for Health Science, IV2 3JH, Inverness, UK aut NATIONALLICENCE 700 1- Liu B. Departments of Pulmonary Oncology and Pathology, The Third Affiliated Hospital of Harbin Medical University, 150040, Harbin, People's Republic of China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 633-637 1699-048X 15:8<633 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer